Sign In
Buy ARDX
Ardelyx Earnings Calls
| Release date | Oct 30, 2025 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.0040 |
| EPS Surprise | 93.32% |
| Revenue estimate | 118.809M |
| Revenue actual | 110.329M |
| Revenue Surprise | -7.14% |
| Release date | Aug 04, 2025 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.0800 |
| EPS Surprise | 38.46% |
| Revenue estimate | 94.629M |
| Revenue actual | 97.662M |
| Revenue Surprise | 3.21% |
| Release date | May 01, 2025 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.170 |
| EPS Surprise | -70.00% |
| Revenue estimate | 79.442M |
| Revenue actual | 74.114M |
| Revenue Surprise | -6.71% |
| Release date | Feb 20, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Revenue estimate | 74.542M |
| Revenue actual | 116.129M |
| Revenue Surprise | 55.79% |
Last 4 Quarters for Ardelyx
Below you can see how ARDX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 20, 2025 |
| Price on release | $5.72 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $5.66 |
| Feb 14, 2025 | $5.79 |
| Feb 18, 2025 | $6.42 |
| Feb 19, 2025 | $6.36 |
| Feb 20, 2025 | $5.72 |
| Feb 21, 2025 | $5.06 |
| Feb 24, 2025 | $5.13 |
| Feb 25, 2025 | $5.18 |
| Feb 26, 2025 | $5.10 |
| 4 days before | 1.06% |
| 4 days after | -10.84% |
| On release day | -11.54% |
| Change in period | -9.89% |
| Release date | May 01, 2025 |
| Price on release | $5.47 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.170 |
| EPS surprise | -70.00% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $5.26 |
| Apr 28, 2025 | $5.35 |
| Apr 29, 2025 | $5.45 |
| Apr 30, 2025 | $5.51 |
| May 01, 2025 | $5.47 |
| May 02, 2025 | $4.13 |
| May 05, 2025 | $3.74 |
| May 06, 2025 | $3.95 |
| May 07, 2025 | $3.70 |
| 4 days before | 3.99% |
| 4 days after | -32.36% |
| On release day | -24.50% |
| Change in period | -29.66% |
| Release date | Aug 04, 2025 |
| Price on release | $4.39 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.0800 |
| EPS surprise | 38.46% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $4.22 |
| Jul 30, 2025 | $4.34 |
| Jul 31, 2025 | $4.24 |
| Aug 01, 2025 | $4.33 |
| Aug 04, 2025 | $4.39 |
| Aug 05, 2025 | $5.13 |
| Aug 06, 2025 | $5.20 |
| Aug 07, 2025 | $5.14 |
| Aug 08, 2025 | $5.21 |
| 4 days before | 4.03% |
| 4 days after | 18.68% |
| On release day | 16.86% |
| Change in period | 23.46% |
| Release date | Oct 30, 2025 |
| Price on release | $5.01 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.0040 |
| EPS surprise | 93.32% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $5.04 |
| Oct 27, 2025 | $5.10 |
| Oct 28, 2025 | $5.11 |
| Oct 29, 2025 | $4.96 |
| Oct 30, 2025 | $5.01 |
| Oct 31, 2025 | $6.06 |
| Nov 03, 2025 | $5.92 |
| Nov 04, 2025 | $5.60 |
| Nov 05, 2025 | $5.95 |
| 4 days before | -0.595% |
| 4 days after | 18.76% |
| On release day | 20.96% |
| Change in period | 18.06% |
Ardelyx Earnings Call Transcript Summary of Q3 2025
Ardelyx reported a strong third quarter 2025 driven by robust commercial execution. Total product revenue was $105.5M and total revenue was $110.3M (up 12% YoY). IBSRELA delivered a record quarter with $78.2M (up 92% YoY) and the company raised full-year IBSRELA revenue guidance to $270M–$275M. XPHOZAH generated $27.4M (up 9% QoQ) with improving prescription pull-through and growing non‑Medicare payer uptake. Gross‑to‑net deductions were ~29–31% in Q3. Operating expenses increased due to commercial and R&D investments (R&D $18.1M; SG&A $83.6M). Net loss was roughly $1M for the quarter; Ardelyx reported positive quarter‑over‑quarter cash flow and ended Q3 with $242.7M in cash, equivalents and short‑term investments. The company announced ARDX‑10531 (a next‑generation, highly soluble/potent NHE3 inhibitor) and plans preclinical and manufacturing work ahead of Phase 1 — signaling a restart of internal development. Leadership changes include CEO commentary welcoming new CFO Sue Hohenleitner and the outgoing CFO Justin Renz. Management reiterated longer‑term commercial targets: IBSRELA >$1B peak and XPHOZAH $750M peak, and emphasized continued investments in patient access, field sales, and pipeline expansion while remaining disciplined with capital.
